다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Nurse practitioner, v.44 no.12, 2019년, pp.21 - 32
Crump, Lauren Hartsell , Benfield, Miranda , Ramey, Caleb , Arcara, Ashley , Yang, Sebin , Brown, Jenna , Mospan, Geoffrey , Mospan, Cortney
AI-Helper
Abstract:In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Su...
N Engl J Med Nestle 361 5 496 2009 10.1056/NEJMra0804595 Psoriasis
Immunology Tang 135 2 112 2012 10.1111/j.1365-2567.2011.03522.x Interleukin-23: as a drug target for autoimmune inflammatory diseases
N Engl J Med Papp 376 16 1551 2017 10.1056/NEJMoa1607017 Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
Paoli 2019 FDA approves Skyrizi for plaque psoriasis. National Psoriasis Foundation
J Am Acad Dermatol Menter 80 4 1029 2019 10.1016/j.jaad.2018.11.057 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Lancet Gordon 392 10148 650 2018 10.1016/S0140-6736(18)31713-6 Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
J Am Acad Dermatol Menter 60 4 643 2009 10.1016/j.jaad.2008.12.032 Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
J Am Acad Dermatol Gold 79 2 287 2018 10.1016/j.jaad.2018.03.040 Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials
Lancet Cahn 393 10167 143 2019 10.1016/S0140-6736(18)32462-0 Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Eur J Rheumatol Sözen 4 1 46 2017 10.5152/eurjrheum.2016.048 An overview and management of osteoporosis
J Clin Endocrinol Metab Eastell 104 5 1595 2019 10.1210/jc.2019-00221 Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline
N Engl J Med Saag 377 15 1417 2017 10.1056/NEJMoa1708322 Romosozumab or alendronate for fracture prevention in women with osteoporosis
N Engl J Med Cosman 375 16 1532 2016 10.1056/NEJMoa1607948 Romosozumab treatment in postmenopausal women with osteoporosis
Ther Adv Musculoskelet Dis Lewiecki 6 2 48 2014 10.1177/1759720X13510479 Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
Int J Womens Health Fitelson 3 1 2010 Treatment of postpartum depression: clinical, psychological and pharmacological options
Am Fam Physician Hirst 82 8 926 2010 Postpartum major depression
Lancet Meltzer-Brody 392 10152 1058 2018 10.1016/S0140-6736(18)31551-4 Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
N Engl J Med Young 328 17 1230 1993 10.1056/NEJM199304293281704 The occurrence of sleep-disordered breathing among middle-aged adults
Sleep Longstreth 30 1 13 2007 10.1093/sleep/30.1.13 The epidemiology of narcolepsy
Chest Strollo 155 2 364 2019 10.1016/j.chest.2018.11.005 Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study
Sleep Sci Bhattarai 10 1 19 2017 10.5935/1984-0063.20170004 Current and future treatment options for narcolepsy: a review
Ann Neurol Thorpy 85 3 359 2019 10.1002/ana.25423 A randomized study of solriamfetol for excessive sleepiness in narcolepsy
Am J Respir Crit Care Med Schweitzer 199 11 1421 2019 10.1164/rccm.201806-1100OC Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial
BMJ MacNee 332 7551 1202 2006 10.1136/bmj.332.7551.1202 Pathology, pathogenesis, and pathophysiology
Expert Opin Drug Deliv Muralidharan 12 6 947 2015 10.1517/17425247.2015.977783 Dry powder inhalers in COPD, lung inflammation and pulmonary infections
Chest Maltais 153 6 1315 2018 10.1016/j.chest.2018.01.008 _-Blockers in COPD: a cohort study from the TONADO research program
Prev Chronic Dis Noonan 7 1 A12 2010 The prevalence of multiple sclerosis in 3 US communities
Lancet Kappos 391 10127 1263 2018 10.1016/S0140-6736(18)30475-6 Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.